ESR1 and neoplasm: However, the extensive molecular characterization of the initial ER+ PDX models reported here can be further strengthened by deeper analyses of the molecular concordance between each therapy-naïve patient tumor and its derived therapy-naïve PDX tumor line at the genomic, transcriptomic, and proteomic levels.